तुलना करने के लिए मीट्रिक्स | 2565 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध2565पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −10.0x | −15.4x | −0.3x | |
PEG अनुपात | −0.35 | 0.02 | 0.00 | |
क़ीमत/बुक | 4.6x | 7.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 10.9x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 26.1% | 49.0% | |
उचित मूल्य अपसाइड | अनलॉक करें | −3.6% | 6.3% | अनलॉक करें |
PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. Its products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity. The company’s PB-718 that is in b/IIa clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) (PB-718 for obesity and NASH); and PB-1902 that is in phase II clinical trials for the treatment of opioids constipation and obesity. It is also developing GLP-1 for the first-line treatment of type 2 diabetes mellitus and obesity; and PB-722 that has completed the FDA orphan drug qualification certification for use in the treatment of congenital hyperinsulinemia. Additionally, the company is conducting preclinical studies test on PB-2301, a GLP-1/glucose-dependent insulinotropic polypeptide; and PB-2309, a GLP-1/GIP/ glucagon triple receptor agonist for the treatment of type 2 diabetes mellitus, NASH, and obesity. PegBio Co., Ltd. was incorporated in 2008 and is based in Hangzhou, China.